Vivimed Labs Board Approves Q2 Results, Pre-packaged Insolvency Application, and Trading Suspension Revocation Expected
Vivimed Labs reported significant losses for Q2 FY26 with a qualified audit opinion due to unrecorded interest. The board approved applying for pre-packaged insolvency and expects trading suspension revocation.
The approval of a pre-packaged insolvency resolution process and the significant financial losses, compounded by a qualified audit opinion, represent major negative developments that could severely impact the company's future operations and stock value. The potential revocation of trading suspension is positive but overshadowed by the insolvency proceedings.
The company reported substantial losses, both standalone and consolidated, which worsened significantly after accounting for the auditor's qualified opinion on unrecorded interest expenses. The decision to initiate a pre-packaged insolvency resolution process indicates severe financial distress, despite efforts to address it.
* The Board of Directors of Vivimed Labs Limited, at its meeting held on November 13, 2025, approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2025. * The statutory auditors issued a qualified review report due to the company not providing for interest expenses of ₹157.28 million (₹15.73 crore) for the quarter ended September 30, 2025 (and ₹307.11 million / ₹30.71 crore for the half-year) on an accrual basis, deviating from Indian accounting standards. * Management's view: The company is negotiating with bankers for a settlement and is confident of reaching one, hence interest on outstanding loans was not recorded for the quarter. * For the quarter ended September 30, 2025 (Standalone): * Total Revenue: ₹188.19 million (₹18.82 crore) * Net Loss (reported): ₹74.45 million (₹7.45 crore) * Adjusted Net Loss (after qualification): ₹231.73 million (₹23.17 crore) * Basic Earnings Per Share (reported): (₹0.90) * Adjusted Basic Earnings Per Share: (₹2.79) * For the quarter ended September 30, 2025 (Consolidated): * Total Revenue: ₹208.25 million (₹20.83 crore) * Net Loss (reported): ₹73.01 million (₹7.30 crore) * Adjusted Net Loss (after qualification): ₹230.29 million (₹23.03 crore) * Basic Earnings Per Share (reported): (₹0.88) * Adjusted Basic Earnings Per Share: (₹2.78) * The Board approved filing an application with the National Company Law Tribunal (NCLT) under Section 54A and other applicable provisions read with Section 10 of the Insolvency and Bankruptcy Code (IBC) for a pre-packaged insolvency resolution process. * This application is subject to approval by shareholders via a Special Resolution at an Extraordinary General Meeting (EGM), for which a draft notice was approved. * The company also expects the revocation of the suspension in trading of its equity shares from the stock exchanges in a few days, having submitted all relevant documents and paid applicable fees.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.